EASL Podcasts

Discover how clinicians are approaching screening and surveillance in PSC today. From imaging and endoscopy to the promise of new biomarkers, this episode highlights key tools, ongoing challenges, and future directions in improving early detection of cholangiocarcinoma. 

Host:  Debbie Shawcross (King's College London)
Guests:  Jesús Bañales (Donostia University Hospital), Gideon Hirschfield (The Autoimmune and Rare Liver Disease Programme) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-21

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-21).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Artificial intelligence (AI) is opening new opportunities to improve the design, efficiency, and evidence generation of clinical trials. This EASL DeepDive examines its applications in patient selection, stratification, and trial workflows, as well as the emerging role of digital twins in simulating treatment responses. Particular attention is given to the use of AI-enabled real-world data to strengthen clinical evidence, while addressing questions of scientific validity, bias, and practical limitations.

Hepatocellular carcinoma (HCC) surveillance is a cornerstone of liver disease management, yet uncertainty persists around who to screen, when to initiate surveillance, and which modalities to use. Evolving risk profiles and variation across guidelines have added complexity to clinical decision-making. In this podcast, we revisit the fundamentals of HCC screening, focusing on practical, evidence-based approaches to patient selection, timing, and surveillance strategies.

Host: Mattias Mandorfer (Medical University of Vienna)
Guests: Peter Jepsen (Aarhus University), Amit Singal (UT Southwestern Medical Center)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-20

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-20).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

This episode explores psychohepatology, examining the gut–liver–brain axis and the bidirectional links between liver disease and mental health. Discussion covers addiction biology, the impact of trauma and post-traumatic stress disorder (PTSD) on alcohol use, and the high prevalence of depression and anxiety in cirrhosis, highlighting integrated approaches to liver and mental health care. 

Host: Mads Israelsen (Odense University Hospital)
Guests: Nicola Kalk (South London and Maudsley NHS Foundation Trust), Victoria Kronsten (King's College London) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-19

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-19).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

This EASL Deep Dive explores key updates from the EASL Clinical Practice Guidelines on hepatocellular carcinoma (HCC), with a practical focus on diagnosis and treatment selection. Experts will discuss evolving imaging and diagnostic criteria, patient selection for surgery and locoregional therapies, and how to adapt management according to response to systemic treatment. The session will also highlight the growing importance of multidisciplinary, individualised care across the HCC treatment pathway.

This episode of Talk Liver to Me explores the practical use of resmetirom and semaglutide in MASH, based on the 2026 EASL–EASD–EASO Guidance. Experts discuss who may benefit from treatment, when to initiate therapy, and how to monitor response and efficacy in clinical practice. 

Host:  Debbie Shawcross (EASL)
Guests:  Andreea Ciudin (EASO), Amalia Gastaldelli (EASD), Frank Tacke (EASL) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-18

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-18).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Liver disease represents a major and under-recognised public health challenge across Africa, driven by a complex interplay of viral hepatitis, rising metabolic dysfunction-associated steatotic liver disease, and a high burden of hepatocellular carcinoma (HCC). Despite this, awareness, surveillance, and access to care remain limited. In this podcast, we explore the evolving epidemiology of liver disease across the continent, highlighting key drivers, regional variations, and gaps in diagnosis and treatment. Why does the burden remain so under-recognised, and what are the priorities for prevention, early detection, and equitable care in Africa?

Host: Debbie Shawcross (King's College London)
Guests: Kwame Asomoah (University of Ghana Business School) and Wendy Spearman (University of Cape Town) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-17

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-17).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

This webinar explores the role of genetic testing in diagnosing Progressive Familial Intrahepatic Cholestasis (PFIC). Attendees will review key test types, understand the principles behind modern genomic technologies, and learn how to position these tests in the diagnostic approach of a person with a suspicion of PFIC and how to navigate common challenges in interpreting genetic results. The session will also highlight emerging trends shaping the future of genetic diagnostics in hepatology. 

Learning objectives 

• Understand the genetic drivers of PFIC and the utility of their testing. 
• Describe basic principles behind modern diagnostic genetic testing relevant to hepatology. 
• Appropriately position genetic testing in the approach of a person suspected to have PFIC. 
• Recognize common challenges in interpreting these genetic findings and linking them with the clinical presentation. 
• Outline emerging trends influencing the future of genetic diagnostics in hepatology

This webinar has received educational grants from IPSEN. IPSEN has had no input into the programme, content, or faculty selection.

Acute liver failure (ALF) is a rare but life-threatening condition requiring rapid recognition and decisive management. Early decisions around investigation, escalation, and referral can significantly impact outcomes. Despite advances in care, variation in practice and avoidable pitfalls remain common. In this podcast, we take a practical, case-based approach to the key “dos and don’ts” in ALF management, focusing on early diagnosis, initial stabilisation, appropriate investigations, and timely referral to specialist centres. What should clinicians prioritise, what should be avoided, and how can we optimise care in the critical early stages of acute liver failure?

Host: Mattias Mandorfer (Medical University of Vienna)
Guests: William Bernal (King's College London), Nigel Heaton (King's College London) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-16

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-16).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Endohepatology is emerging as a novel approach to liver disease assessment, with the potential to combine EUS-guided liver biopsy, portal pressure measurement, and variceal evaluation within a single session. This “one-stop shop” model could streamline diagnostic pathways and enable integrated, real-time clinical decision-making. However, this innovation comes at a time when hepatology is moving increasingly towards non-invasive testing strategies. Questions therefore remain around its appropriateness, clinical utility, and feasibility in routine practice. In this podcast, we explore whether this approach represents meaningful progress or premature adoption, examining current evidence, potential benefits, and practical challenges. 

This episode is produced in collaboration with the European Society of Gastrointestinal Endoscopy (ESGE).

Host:  Tom Marjot (King's College London)
Guests:  Juan Abraldes (University of Alberta), Hannah van Malenstein (University Hospital Leuven) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-15

Thank you to our healthcare industry partners for their support. For more information, please visit EASLCampus.eu.

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-15).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.